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PURPOSE. Diabetic retinopathy (DR) is a common microvascular complication of type 2
diabetes (T2DM). Genome-wide association studies (GWAS) had identified novel DR-
susceptibility genetic variants in various populations. We examined the associations of these
DR-associated single nucleotide polymorphisms (SNPs) with severe DR in a Chinese T2DM
cohort.
METHODS. Cross-sectional case-control studies on sight-threatening DR (STDR) and prolifer-
ative DR (PDR) were performed. We genotyped 38 SNPs showing top association signals with
DR in previous GWAS in 567 STDR cases, including 309 with PDR and 1490 non-DR controls.
Multiple logistic regression models with adjustment for conventional risk factors, including
age, sex, duration of diabetes, and presence of hypertension, were employed.
RESULTS. The strongest association was found at INSR rs2115386, an intronic SNP of INSR:
Padjusted ¼ 9.13 3 104 (odds ratio [OR],1.28; 95% confidence interval [95%CI], 1.11–1.48)
for STDR, and Padjusted¼ 1.12 3 104 (OR [95%CI],1.44 [1.20–1.74]) for PDR. rs599019
located downstream of COLEC12 (Padjusted ¼ 0.019; OR [95%CI],1.19 [1.03–1.38]) and
rs4462262 located at an intergenic region between ZWINT and MRPS35P3 (Padjusted ¼ 0.041;
OR [95%CI],1.38[1.01–1.89]) also were significantly associated with STDR, but not with PDR
alone. On the other hand, MYT1L-LOC729897 rs10199521 (Padjusted ¼ 0.022; OR
[95%CI],1.25 [1.03–1.51]) and API5 rs899036 (Padjusted ¼ 0.049; OR [95%CI],1.36 [1.00–
1.85]) showed significant independent associations only with PDR. Similar results were
obtained when hemoglobin A1c also was included in the adjustment models.
CONCLUSIONS. We demonstrated the significant and independent associations of several GWAS-
identified SNPs with DR in Chinese T2DM patients with severe DR. The findings on INSR
rs2115386 are supportive of the role of insulin resistance, or the compensatory
hyperinsulinemia, in the pathogenesis of DR.
Keywords: diabetic retinopathy, sight-threatening diabetic retinopathy, proliferative diabetic
retinopathy, genome-wide association studies, genetic variants, INSR
Type 2 diabetes mellitus (T2DM) is a chronic diseasecurrently posing huge burdens on individual and public
health worldwide. This disease has been considered as a major
source of morbidity and mortality attributable to its associated
acute or chronic complications. Diabetic retinopathy (DR) is
one of the most common chronic microvascular complications
of T2DM and is the leading cause of irreversible loss of vision
among working populations in developed countries.1 Preva-
lence of DR in the Caucasian populations has been estimated to
range from 19% to 30% among subjects with T2DM.2–5 A recent
large-scale systematic screening study for DR, using the English
National Screening Program grading standard,6 reported a high
prevalence of DR in 39% of the Hong Kong Chinese diabetic
population.7 The prevalence of the more advanced stage of DR,
sight-threatening DR (STDR), which is defined as the presence
of either preproliferative DR, proliferative DR (PDR), or
maculopathy, was found to have reached 9.8%.7
Over the past few decades, extensive epidemiologic studies
have identified important risk factors for DR, such as duration
of diabetes, hypertension (HT), and inadequate control of
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glycemia. However, clinical studies reveal a substantial
variation in the onset and severity of retinopathy, which is
not fully explained by these known risk factors.8,9 Indeed,
some patients with poor control of glycemia or blood pressure
(BP) may be found after long diabetes duration to have no
DR.10 These data suggest that genetic factors also have a role in
the development of DR. The heritability of DR has been
estimated to be approximately 25%.11,12 Understanding the
genetic basis of DR will help to identify the underlying
pathophysiologic mechanisms. This genetic information also
may contribute to the risk profiling of DR in diabetic patients,
thus facilitating their early diagnosis and disease management.
Robust associations of the DR-susceptibility variants would
serve as the basis for their use as genetic markers to
supplement the prediction by conventional clinical predictors
for more accurate risk stratification. Advancing from the
traditional candidate gene approach, which focused only on a
small number of potential candidates implicated in the
pathogenesis of DR, the genome-wide association studies
(GWAS) have provided an alternative strategy for detecting
novel genetic loci for DR. Several GWAS in various ethnic
groups have identified novel susceptibility genetic variants for
DR in T1DM and T2DM cohorts.13–16 So far, only a few
replication studies have been conducted to validate these
novel associations.17–20 Whether these DR-associated variants
identified in previous GWAS all show an impact on the
development of DR in the Chinese population has not been
systematically investigated. The primary objective of the
present study was to evaluate the associations of the GWAS
identified DR-associated single nucleotide polymorphisms
(SNPs) with severe DR in Hong Kong Chinese patients with
T2DM.
SUBJECTS AND METHODS
Subjects
Two cross-sectional case-control studies on STDR and PDR
were performed in a total of 2057 Southern Chinese patients
with T2DM. This study involved 1490 non-DR controls and 567
STDR cases, including 309 subjects who had PDR. Type 2
diabetes mellitus was defined as fulfilling at least one of the
following criteria, according to the American Diabetes
Association 2008 diagnostic criteria:21 fasting plasma glucose
(FPG) ‡ 7 mmol/l, 2-hour glucose during oral glucose
tolerance test (OGTT) ‡ 11.1 mmol/l, showing symptoms of
hyperglycemia and a causal plasma glucose ‡ 11.1 mmol/l, or
on antidiabetic treatment (insulin or other glucose-lowering
medications). All non-DR controls (n ¼ 1490) were recruited
from the Hong Kong West Diabetes Registry (HKWDR).22
Unrelated T2DM patients, who were on regular follow-up at
the diabetes clinics of the Queen Mary Hospital, were invited
to participate in the HKWDR, which was commenced in 2008.
At 12- to 18-month intervals, the participants underwent
extensive medical assessments and laboratory examinations to
assess for the presence of diabetic complications, including DR
as determined by the 2-field digital fundus photographs
assessed by specialist ophthalmologists. The STDR cases in
this study were recruited from the HKWDR, ophthalmology
clinics at Queen Mary Hospital, Tseung Kwan O Hospital, and
United Christian Hospital, Hong Kong. At assessment, detailed
medication, and medical and family histories were recorded
using a standardized questionnaire; anthropometric (weight,
height, waist circumference) and clinical (age, sex, BP, and
hemoglobin A1c [HbA1c]) data were collected. Duration of
diabetes was defined as the difference between the time at
diagnosis and time at ascertainment of STDR. Hypertension
was defined as BP ‡ 140/90 mm Hg or taking antihypertensive
drugs. After an overnight fast of at least 8 hours, blood samples
for biochemical and genetic analysis were drawn with written
informed consents were obtained. Ethical approvals were
obtained from the Institutional Review Boards (IRB) of the 3
hospitals (IRB references: UW 07-378; UW 13-237; KC/KE-13-
0087/FR-1). All study procedures of this research were in
accordance with the Declaration of Helsinki.
Phenotype Characterization
The current study included Chinese T2DM patients either
without retinopathy or with STDR, determined on the basis of
digital, color fundal photographs taken with fundus cameras
(TRC50-DX type 1A; Topcon, Tokyo, Japan) with 2 photo-
graphic fields (458) for each eye (one centered at the macula
and the other centered at the optic disc). Visual acuity was
assessed with the Early Treatment of Diabetic Retinopathy
Study (ETDRS) chart using the auto-chart projector (Auto-Chart
Projector ACP-7EM; Topcon). All STDR cases have been
assessed systematically by specialist ophthalmologists who
determined the presence and graded the severity of DR
according to the English National Screening Program guide-
lines.6 Cases with STDR were defined as patients with either
pre-PDR (graded R2), PDR (graded R3), or showing features of
maculopathy (graded M1).7 Non-DR controls were T2DM
patients without retinopathy (graded R0). Subjects with
background DR (graded R1) or ungradable fundus photographs
were excluded from the current study.
Genetic Analysis
We selected 38 previously reported DR-associated SNPs to
examine for their associations with severe DR (STDR and PDR)
in a Southern Chinese population. These SNPs have shown top
association signals with P < 53104 as reported in at least one
of the available GWAS13–16 published before the commence-
ment of genotyping in June 2014. For the reported SNPs which
showed strong linkage disequilibrium (LD; r2 > 0.9) on the
1000 Genome Project for Southern Chinese, only one
representative SNP with stronger association was selected for
genotyping. Single nucleotide polymorphisms that were
monomorphic or with minor allele frequency (MAF) < 1% in
the Southern Chinese population were not included in the
current study. Genomic DNA for genetic analysis was extracted
using the ReliaPrep Blood gDNA Miniprep System (Promega,
Madison, WI, USA) extraction kits according to the manufac-
turer’s instructions. All SNPs were genotyped using the
Sequenom iPLEX Gold genotyping platform at the Center for
Genomic Sciences of the University of Hong Kong. Four SNPs
that were incompatible with the Sequenom multiplexing
design were replaced by a corresponding proxy SNP (with r2
> 0.8) for genotyping (rs2038823 replaced by rs16953072,
rs1970671 replaced by rs1125313, rs10910200 replaced by
rs6662352, and rs11867934 replaced by rs117421492). Geno-
typing of rs9565164 and rs1399634 was unsuccessful and was
not included in the analyses. Hardy-Weinberg Equilibrium
(HWE) for each SNP was examined by the exact test using
PLINK version 1.09.23 To ensure the accuracy of genotype
data, we excluded 3 SNPs (rs4470583, rs13163610, and
rs6909083) that showed deviation from HWE (P < 0.05/38
SNPs ¼ 1.3 3 103), and 4 SNPs (rs117421492, rs1445754,
rs1125313, and rs2380261) with a call rate of less than 90%,
from further analyses. After quality control, all 3 variants
(rs96565164, rs1399634, and rs2380261) identified in a
GWAS16 conducted by Sheu et al.16 were excluded for the
reasons mentioned above. Thus, for the final analysis, a total of
29 SNPs that were identified from the remaining GWAS13–15
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and passed quality measures were examined. The average
successful call rate of SNPs that passed quality control was
99.0% and the concordant rate was 99.98% based on 20
duplicated samples.
Statistical Analysis
All statistical analyses were conducted using PLINK version
1.0923 and IBM SPSS Statistics 21. All continuous variables were
summarized as mean 6 SD or median with interquartile range
as appropriate. Variables that did not follow a normal
distribution as reflected by a significant P value in the
Kolmogorov-Smirnov test were natural-logarithmically trans-
formed before analyses. Continuous and categorical clinical
parameters were compared between the case and control
groups by 1-way ANOVA and the v2 test, respectively. The
associations between the SNPs and severe DR were examined
by the multiple logistic regression analyses with adjustment for
the conventional risk factors, including age, sex, duration of
diabetes and the presence of HT (Model 1), under an additive
model. Hemoglobin A1c also was included as an additional
covariate in Model 2. A 2-tailed P < 0.05 was considered as
statistically significant. Bonferroni correction for multiple
testing was used to correct for multiple comparison. The
power of study was calculated using the Genetic Power
Calculator (available in the public domain at http://pngu.mgh.
harvard.edu/~purcell/gpc/).24
RESULTS
Association With STDR
A total of 29 DR-associated SNPs identified in previous
GWAS13–15 was successfully genotyped in 1490 non-DR
controls and 567 STDR cases, among whom 309 had PDR.
Table 1 shows the clinical characteristics of the study
participants. As expected, the subjects with STDR or PDR
had a longer duration of diabetes, more of them also were
affected with HT, and they had greater HbA1c when compared
to the non-DR subjects.
Assuming an STDR prevalence of 9.8%,7 the current sample
size was sufficient to achieve over 80% power for detecting
significant associations of SNPs with MAF ‡ 0.2 and effect sizes
greater than 1.25, at a significance level of 0.05. On the other
hand, our study was underpowered to detect associations of
SNPs with modest effect sizes and lower MAF (See Supple-
mentary Fig. S1). Table 2 shows the association analyses with
STDR. Of the 29 SNPs, 13 showed consistent direction of effect
with the previous reports, including the strongest association
at an intronic SNP rs2115386 of the insulin receptor (INSR)
gene. rs2115386 was significantly associated with STDR after
adjustment for the conventional confounding factors including
age, sex, duration of diabetes, and the presence of HT (Padjusted
¼ 9.133 104; odds ratio [OR], 1.28; 95% confidence interval
[95%CI], 1.11–1.48). This association survived the multiple
testing corrections. rs599019 located downstream of COLEC12
(Padjusted ¼ 0.019; OR [95%CI], 1.19 [1.03–1.38]) and an
intergenic SNP rs4462262 located at the ZWINT-MRPS35P3
locus (Padjusted ¼ 0.041; OR [95%CI], 1.38 [1.01–1.89]) also
showed significant associations with STDR, but were unable to
survive the stringent Bonferroni correction for multiple testing.
All these associations remained significantly associated with
STDR when HbA1c also was included in the adjustment model
(INSR rs2115386, Padjusted ¼ 7.183 104; COLEC12 rs599019,
Padjusted ¼ 9.093 103; ZWINT-MRPS35P3 rs4462262, Padjusted
¼ 0.031). Supplementary Table S1 shows the comparison of
association results between the current study and the original
reports.
Association With PDR
We further examined the associations of these SNPs with PDR.
Table 3 shows the association analyses with PDR. The INRS
rs2115386 again showed a significant association with PDR
even after adjustment for the confounding factors (Padjusted ¼
1.123104; OR [95%CI], 1.44 [1.20–1.73]) and this association
was able to survive the correction for multiple testing.
However, COLEC12 rs599019 and ZWINT-MRPS35P3
rs4462262, which were significantly associated with STDR,
failed to show a significant association with the advanced stage
PDR alone. On the other hand, an intergenic SNP rs10199521
at the MYT1L-LOC729897 locus (Padjusted¼0.022; OR [95%CI],
1.25 [1.03–1.51]) and an intronic variant of API5 rs899036
(Padjusted¼ 0.049; OR [95%CI], 1.36 [1.00–1.85]) only showed
significant associations with PDR. When HbA1c was included
in the adjustment model, INSR rs2115386 (Padjusted ¼ 1.23 3
TABLE 1. Clinical Characteristics of Study Participants
Variables Non-DR STDR PDR
Number 1490 567 309
Age, y 62.79 6 12.76 62.62 6 11.17 59.92 6 11.16*
Diabetes duration, y† 7 (3–12) 14 (6–23)* 14 (5–23)*
Sex, male; % 56.6 57.0 58.6
HT, % 82.9 95.0* 94.8*
SBP,‡ mm Hg 144.42 6 21.70 151.78 6 22.04* 153.18 6 20.92*
DBP,‡ mm Hg 78.79 6 10.09 79.08 6 11.33 79.97 6 11.54
HbA1c, %† 7.1 (6.5–7.8) 7.5 (6.8–8.6)* 7.5 (6.7–8.5)*
BMI, kg/m2 26.27 6 4.15 25.70 6 4.0 26.11 6 4.24
WC, cm M: 92.17 6 9.88 M: 90.36 6 9.80 M:90.66 6 10.17
F: 86.15 6 11.07 F: 87.45 6 11.06 F:88.55 6 11.66
Dyslipidemia, % 68.9 67.0 68.9
Ever smoke, % 33.6 33.7 36.6
Ever drink, % 39.1 35.8 35.6
Hypertension was defined as BP ‡ 140/9 mm Hg or taking antihypertensive drugs. BMI, body mass index; WC, waist circumference; SBP, systolic
blood pressure; DBP, diastolic blood pressure.
* Significant association (P < 0.05) after correction for multiple comparison.
† Natural-log transformed before analysis.
‡ SBPþ 10 mm Hg and DBPþ 5 mm Hg if on antihypertensive drugs. Dyslipidemia was indicated by a documented history of dyslipidemia in
patients’ records or taking lipid-lowering drugs.
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104) and MYT1L-LOC729897 rs10199521 (Padjusted ¼ 0.016)
also remained significantly associated with PDR, but API5
rs899036 (Padjusted ¼ 0.058) was unable to reach statistical
significance after the adjustment.
DISCUSSION
In the present study, we evaluated the associations of 29
previously reported DR-associated SNPs with STDR and PDR in
a total of 2057 Chinese patients with T2DM. We successfully
confirmed the associations of several previously reported DR-
susceptibility genetic variants in our population, including
INSR rs2115386, which remained significantly and indepen-
dently associated with STDR and PDR even after the stringent
Bonferroni correction for multiple testing.
Among the studied loci, the strongest association was found
at the INSR locus. This association could be biologically
relevant, since INSR encodes the insulin receptor which has a
key role in insulin signaling in insulin-sensitive tissues,
including retina.25 In the retina, it has been shown that
disrupted insulin receptor signaling leads to cell dysfunction,25
and insulin provides trophic support for retinal neurons
through a PI3-kinase/Akt-dependent pathway.26 Animal studies
also have demonstrated that diabetes progressively impaired
the constitutive retinal insulin receptor/Akt pro-survival
signaling.27 On the other hand, insulin receptors on retinal
endothelial cells have been shown to regulate the expression
of vascular mediators, such as VEGF and have been implicated
in the control of retinal endothelial cell growth, neovascular-
ization, and DR.28 Insulin resistance, which often is accompa-
nied by hyperinsulinemia, has been implicated in DR29 and
shown to be an independent predictor of PDR in T2DM
patients.30 Hyperinsulinemia is a cause of endothelial dysfunc-
tion,31 and has been suggested to contribute to the altered
retinal microvascular blood flow involved in the development
of DR.32 Our findings on the significant association of INSR
TABLE 2. Association Analysis of STDR
Nearest Gene(s) SNP CHR Position A1 A2
MAF Model 1 Model 2
No-DR STDR OR (95%CI) Padjusted OR (95%CI) Padjusted
IGSF21-KLHDC7A rs3007729* 1 18795255 T C 0.32 0.31 0.90 (0.76–1.05) 0.183 0.91 (0.77–1.07) 0.243
MYSM1 rs2811893† 1 59162148 C T 0.34 0.35 1.02 (0.88–1.19) 0.788 0.98 (0.83–1.14) 0.762
SCYL1BP1 rs6427247‡§ 1 170380480 G A 0.25 0.26 1.03 (0.88–1.22) 0.702 1.03 (0.87–1.22) 0.715
TNFSF4-
LOC730070 rs1342038* 1 173301516 C T 0.42 0.42 0.97 (0.84–1.13) 0.734 0.97 (0.83–1.13) 0.675
KIAA1804-KCNK1 rs6662352*jj 1 233642172 T G 0.35 0.34 0.94 (0.80–1.10) 0.423 0.93 (0.79–1.09) 0.372
AKT3-ZNF238 rs10927101* 1 244173872 C A 0.28 0.30 1.09 (0.92–1.28) 0.318 1.09 (0.92–1.28) 0.325
AKT3-ZNF238 rs476141* 1 244176424 A C 0.20 0.19 0.91 (0.76–1.10) 0.343 0.91 (0.75–1.10) 0.323
MYT1L-
LOC729897 rs10199521*§ 2 2519513 T C 0.35 0.37 1.11 (0.95–1.29) 0.182 1.12 (0.96–1.31) 0.144
LINC01249 rs699549‡ 2 4705263 T C 0.23 0.22 0.91 (0.77–1.09) 0.315 0.93 (0.78–1.11) 0.399
HNMT rs763970‡§ 2 138636133 A C 0.30 0.31 1.03 (0.89–1.21) 0.675 1.05 (0.89–1.23) 0.564
BFSP2 rs1197310‡ 3 133128224 A T 0.49 0.49 1.02 (0.88–1.18) 0.786 1.00 (0.86–1.16) 0.989
LEKR1-CCN1 rs13064954*§ 3 156854742 A G 0.08 0.09 0.98 (0.76–1.27) 0.874 1.04 (0.80–1.35) 0.786
KRT18P34-VEPH1 rs9866141*§ 3 156950579 T C 0.08 0.09 1.14 (0.88–1.48) 0.336 1.15 (0.88–1.50) 0.308
C5orf36 rs17376456†§ 5 93557702 G A 0.05 0.04 0.76 (0.53–1.11) 0.155 0.84 (0.58–1.22) 0.354
CAMK4 rs2300782‡ 5 110788785 T C 0.41 0.39 0.91 (0.78–1.05) 0.200 0.90 (0.77–1.04) 0.162
C6orf170 rs17083119‡ 6 121402110 G A 0.12 0.11 0.89 (0.71–1.13) 0.348 0.91 (0.72–1.16) 0.445
LOC729200-
MAP3K7IP2 rs7772697* 6 149435111 C T 0.18 0.18 1.07 (0.88–1.30) 0.481 1.05 (0.86–1.28) 0.617
CREB5 rs11765845* 7 28391142 A G 0.27 0.26 0.95 (0.8–1.12) 0.513 0.92 (0.78–1.10) 0.360
PLXDC2-NEBL rs12219125†§ 10 20593087 T G 0.11 0.12 1.02 (0.81–1.29) 0.863 1.08 (0.85–1.36) 0.539
ARHGAP22 rs4838605†§ 10 49699957 C T 0.10 0.10 1.02 (0.80–1.30) 0.857 1.10 (0.86–1.41) 0.438
ARHGAP22 rs11101357† 10 49723300 A G 0.10 0.10 0.99 (0.77–1.27) 0.953 1.07 (0.83–1.38) 0.582
ZWINT-
MRPS35P3 rs4462262† 10 59189178 T C 0.05 0.06 1.38 (1.01–1.89) 0.041 1.41 (1.03–1.93) 0.031
API5 rs899036‡ 11 41682910 C A 0.08 0.1 1.14 (0.88–1.48) 0.310 1.14 (0.88–1.47) 0.336
CNTN5 rs10501943‡§ 11 99946999 C T 0.03 0.03 1.41 (0.90–2.20) 0.131 1.46 (0.92–2.30) 0.106
HS6ST3 rs16953072†§jj 13 96950313 T G 0.05 0.05 0.96 (0.68–1.36) 0.827 0.99 (0.70–1.41) 0.975
FMN1 rs10519765‡§ 15 33205424 A G 0.11 0.09 0.80 (0.63–1.02) 0.070 0.82 (0.64–1.05) 0.111
COLEC12 rs599019‡ 18 294495 C A 0.46 0.49 1.19 (1.03–1.38) 0.019 1.22 (1.05–1.42) 9.09 3 103
INSR rs2115386*§ 19 7196565 C T 0.47 0.53 1.28 (1.11–1.48) 9.13 3 10–4 1.29 (1.11–1.50) 7.18 3 10–4
VSTM2B-POP4 rs10403021*§ 19 30079604 T C 0.28 0.28 0.98 (0.83–1.15) 0.761 1.00 (0.85–1.18) 0.991
Single nucleotide polymorphisms ranked by chromosomal position. Single nucleotide polymorphisms showed statistically significant association
with STDR are highlighted in bold. Chromosomal position corresponds to human reference genome hg19. Odds ratio corresponds to the minor
allele (A1). Model 1: Adjusted for age, sex, duration of diabetes and presence of HT. Model 2: Adjusted for age, sex, duration of diabetes, presence of
HT and HbA1c. CHR, chromosome; A1, minor allele; A2, major allele; MAF, minor allele frequency.
* Significantly associated SNPs in Reference 14.
† Significantly associated SNPs in Reference 15.
‡ Significantly associated SNPs in Reference 13.
§ Single nucleotide polymorphisms showing consistent direction of effect as in the original reports. Single nucleotide polymorphism remained
significant after Bonferroni correction for multiple testing is underlined.
jj rs6662352 is the proxy SNP of rs10910200 (r2 ¼ 0.99) and rs16953072 is the proxy SNP of rs2038823 (r2 ¼ 1).
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rs2115386 are supportive of a role of insulin resistance, or the
compensatory hyperinsulinemia, in the pathogenesis of DR.
The association of rs2115386 with severe DR (PDR or
diabetic macular edema) was first identified in a GWAS meta-
analysis of two T1DM cohorts, including a total of 2829
subjects from the Epidemiology of Diabetes Intervention and
Control Trial (EDIC) and the Genetics of Kidney in Diabetes
(GoKinD) studies.14 In that study, none of the reported
associations had reached genome-wide significance.14 Al-
though not being the most significant association identified
in that study, INSR rs2115386 was a variant that showed an
association of marginal genome-wide significance (P ¼ 2.86 3
106) with severe DR that deserved further investigation.14 The
small number of cases with PDR and different inclusion criteria
for cases and controls may explain why another study, which
examined only 163 cases with non-PDR or PDR and 300
controls with no DR or mild DR, was unable to replicate the
association of this SNP.18 Further replication in other indepen-
dent studies with similar phenotype characterization would be
essential to validate this association. rs2115386 is located at
intron 2 of INSR and it shows no obvious functional
significance (RegulomeDB score, 5).33 It may be linked with
the disease-causing variant that is yet to be identified. Fine-
mapping and deep-sequencing analyses to further refine the
INSR gene region would serve to identify the causative
variants. Functional studies to elucidate the role of the insulin
receptor in the pathogenesis of DR also are warranted. Our
findings that this SNP was significantly associated with STDR
and PDR would strongly support INSR as a susceptibility gene
for DR. The effect of INSR could possibly be more evident in
PDR, as demonstrated in the current study. Our successful
replication of this association in a T2DM cohort has provided
support for a shared underlying pathogenetic pathway for DR
in T1DM and T2DM.
As with many other complex diseases, the investigations of
the genetic basis for DR have benefited from the advanced
microarray-based genotyping technologies in recent years. In
2010, the first GWAS for DR involving 103 moderate to severe
TABLE 3. Association Analysis of PDR
Nearest Gene(s) SNP CHR Position A1 A2
MAF Model 1 Model 2
No-DR PDR OR (95%CI) Padjusted OR (95%CI) Padjusted
IGSF21-KLHDC7A rs3007729* 1 18795255 T C 0.32 0.30 0.86 (0.70–1.06) 0.160 0.88 (0.72–1.08) 0.228
MYSM1 rs2811893† 1 59162148 C T 0.34 0.35 1.04 (0.86–1.26) 0.687 1.00 (0.82–1.22) 0.993
SCYL1BP1 rs6427247‡§ 1 170380480 G A 0.25 0.25 1.01 (0.82–1.24) 0.932 1.00 (0.81–1.24) 0.985
TNFSF4-
LOC730070 rs1342038* 1 173301516 C T 0.42 0.42 0.97 (0.80–1.16) 0.708 0.96 (0.79–1.16) 0.651
KIAA1804-KCNK1 rs6662352*jj 1 233642172 T G 0.35 0.33 0.89 (0.73–1.08) 0.228 0.86 (0.70–1.05) 0.139
AKT3-ZNF238 rs10927101* 1 244173872 C A 0.28 0.31 1.12 (0.92–1.37) 0.263 1.10 (0.89–1.35) 0.373
AKT3-ZNF238 rs476141* 1 244176424 A C 0.20 0.19 0.95 (0.75–1.20) 0.664 0.93 (0.73–1.18) 0.534
MYT1L-
LOC729897 rs10199521*§ 2 2519513 T C 0.35 0.39 1.25 (1.03–1.51) 0.022 1.27 (1.05–1.54) 0.016
LINC01249 rs699549‡§ 2 4705263 T C 0.23 0.25 1.07 (0.87–1.33) 0.520 1.09 (0.87–1.35) 0.461
HNMT rs763970‡ 2 138636133 A C 0.30 0.29 0.94 (0.77–1.14) 0.512 0.95 (0.78–1.16) 0.619
BFSP2 rs1197310‡ 3 133128224 A T 0.49 0.49 1.02 (0.85–1.22) 0.862 1.00 (0.83–1.20) 0.975
LEKR1-CCN1 rs13064954*§ 3 156854742 A G 0.08 0.08 0.85 (0.60–1.19) 0.335 0.89 (0.63–1.26) 0.511
KRT18P34-VEPH1 rs9866141*§ 3 156950579 T C 0.08 0.08 1.03 (0.74–1.43) 0.871 1.00 (0.71–1.41) 0.996
C5orf36 rs17376456†§ 5 93557702 G A 0.05 0.04 0.84 (0.53–1.33) 0.453 0.95 (0.60–1.50) 0.826
CAMK4 rs2300782‡ 5 110788785 T C 0.41 0.38 0.84 (0.70–1.02) 0.071 0.83 (0.69–1.01) 0.056
C6orf170 rs17083119‡ 6 121402110 G A 0.12 0.10 0.84 (0.62–1.14) 0.270 0.89 (0.66–1.21) 0.469
LOC729200-
MAP3K7IP2 rs7772697* 6 149435111 C T 0.18 0.18 1.02 (0.80–1.29) 0.898 0.98 (0.77–1.25) 0.876
CREB5 rs11765845* 7 28391142 A G 0.27 0.26 0.94 (0.76–1.16) 0.580 0.93 (0.75–1.15) 0.504
PLXDC2-NEBL rs12219125† 10 20593087 T G 0.11 0.11 0.94 (0.70–1.26) 0.677 0.99 (0.73–1.33) 0.942
ARHGAP22 rs4838605†§ 10 49699957 C T 0.10 0.11 1.05 (0.77–1.42) 0.777 1.17 (0.86–1.59) 0.316
ARHGAP22 rs11101357† 10 49723300 A G 0.10 0.10 0.98 (0.71–1.34) 0.879 1.08 (0.79–1.48) 0.628
ZWINT-MRPS35P3 rs4462262† 10 59189178 T C 0.05 0.05 1.10 (0.72–1.67) 0.663 1.12 (0.73–1.72) 0.595
API5 rs899036‡ 11 41682910 C A 0.08 0.11 1.36 (1.00–1.85) 0.049 1.35 (0.99–1.84) 0.058
CNTN5 rs10501943‡§ 11 99946999 C T 0.03 0.04 1.60 (0.95–2.71) 0.077 1.63 (0.95–2.79) 0.076
HS6ST3 rs16953072†jj 13 96950313 T G 0.05 0.06 1.15 (0.77–1.73) 0.493 1.17 (0.77–1.76) 0.459
FMN1 rs10519765‡§ 15 33205424 A G 0.11 0.10 0.85 (0.63–1.15) 0.281 0.85 (0.62–1.16) 0.308
COLEC12 rs599019‡ 18 294495 C A 0.46 0.47 1.13 (0.94–1.36) 0.201 1.16 (0.96–1.4) 0.132
INSR rs2115386*§ 19 7196565 C T 0.47 0.55 1.44 (1.20–1.73) 1.12 3 10–4 1.44 (1.20–1.74) 1.23 3 10–4
VSTM2B-POP4 rs10403021*§ 19 30079604 T C 0.28 0.28 0.95 (0.78–1.17) 0.634 1.01 (0.82–1.24) 0.954
Single nucleotide polymorphisms ranked by chromosomal position. Single nucleotide polymorphisms showed statistically significant association
with PDR are highlighted in bold. Chromosomal position corresponds to human reference genome hg19. Odds ratio corresponds to the minor allele
(A1). Model 1: Adjusted for age, sex, duration of diabetes and presence of HT. Model 2: Adjusted for age, sex, duration of diabetes, presence of HT
and HbA1c. CHR, chromosome; A1, minor allele; A2, major allele; MAF, minor allele frequency.
* Significantly associated SNPs in Reference 14.
† Significantly associated SNPs in Reference 15.
‡ Significantly associated SNPs in Reference 13.
§ Single nucleotide polymorphisms showing consistent direction of effect as in the original reports. Single nucleotide polymorphism remained
significant after Bonferroni correction for multiple testing is underlined.
jj rs6662352 is the proxy SNP of rs10910200 (r2 ¼ 0.99) and rs16953072 is the proxy SNP of rs2038823 (r2 ¼ 1).
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non-PDR and PDR cases, and 183 normal to early non-PDR
controls with T2DM of Mexican-American ancestry was
published.13 Several GWAS of DR in different populations
subsequently were published.14–16 Nonetheless, the results of
these GWAS have only yielded limited success with only a few
variants being able to reach genome-wide significance (P  53
108) and these associations were unable to be replicated in
independent GWAS.13–16 Notably, these GWAS generally were
conducted in relatively small sample sizes, based on different
definitions for cases and controls, types of diabetes, and
covariates adjustments. These studies also lacked follow-up
analyses, except for the study of Sheu et al.,16 which included 2
independent replication cohorts. In the current study, we
sought to systematically replicate the top association signals in
a T2DM cohort with a reasonable sample size. Assuming a
STDR prevalence of 9.8%7 and a MAF of 0.2, our current
sample size was sufficient to achieve 68%, 85%, and 94% power
to detect a significant association for an effect size of 1.20,
1.25, and 1.30, respectively, at a significance level of 0.05. We
were able to detect the significant associations of the INSR
variant and several other variants with severe DR with the
current sample size. Among these, the INSR rs2115386,
COLEC12 rs599019, AIP5 rs899036, and MYT1L rs1019952
were previously identified in the Mexican-American or
Caucasian populations. Our successful replication of these
SNPs in an Asian population would provide further support of
the involvement of these loci in DR. We also replicated the
association of ZWINT-MRPS35P3 rs4462262, which was
detected in a Taiwan Chinese population. The unsuccessful
replications of other variants could have been due to lack of
study power to detect those SNPs with relatively lower allele
frequency and modest effect size. Furthermore, the difference
in definitions for cases and controls and the varying covariates
adjustments between studies also might contribute to the
unsuccessful replications. Alternatively, some of these signals
could be false-positive. Further replication studies should be
conducted in independent cohorts of larger sample size to
validate or to reject the associations of these GWAS-identified
variants.
Only a handful of genes or pathways have been shown to be
robustly associated with the development of DR so far.
Possibly, the genetic susceptibility to DR could be conferred
by rare or low frequency variants that were not covered in the
candidate gene analyses and conventional GWAS that mainly
focused on the common variants. The recently developed
Exome-chip or whole exome/genome sequencing have pro-
vided an excellent tool for the discovery of rare, low frequency,
or even population-specific disease-susceptibility variants. The
gene-based tests, which account for the correlations between
variants within the same gene,34 would provide an alternative
approach to the single-variant analyses that often lack the
power to detect the associations of rare variants. Large-scale
meta-analyses with sufficient study power will be essential to
detect more genetic variants with modest effect. Due to cost
and time considerations in using conventional genotyping
platforms, researchers may tend to focus only on the genome-
wide significant signals for replications. Potential susceptibility
variants that showed marginal associations sometimes may be
overlooked for follow-up. Current array-based genotyping
technologies allow analyses of much larger number of variants
simultaneously at reasonable cost. Application of the array-
based genotyping method in future follow-up studies to
include more SNPs would facilitate the identification of more
potential disease-susceptibility variants.
The strength of this study was the well-defined phenotype
and clear grading of DR severity based on the well-established
English National Screening Program guidelines.6 Unlike many
others, the current study only included subjects without DR
(graded R0) as controls. The associations of SNPs identified in
previous GWAS that were based on varying phenotype
definitions have been comprehensively studied in this study
by examining the more broadly defined STDR (including
maculopathy, pre-PDR, and PDR), and the more specifically
defined PDR. Potential confounding was taken into consider-
ation by adjustment for the conventional risk factors. To
maximize the sample size, we have not specifically imposed an
inclusion criterion on the duration of diabetes for controls.
Instead, we accounted for this possible confounding by
adjustment for duration of diabetes in the analyses. During
the preparation of this manuscript, 2 additional GWAS on
DR35,36 were published. However, the current study has not
examined these newly identified DR-associated variants. Our
study would have been strengthened by a more comprehen-
sive examination of all reported DR-susceptibility variants,
including the newly identified SNPs as well as those that failed
to pass quality check. The current study also was limited by the
fact that it was slightly underpowered to detect the associa-
tions of variants with lower allele frequencies and modest
effect.
In conclusion, we have successfully confirmed the signifi-
cant and independent associations of several SNPs identified in
previous GWAS with severe DR (STDR and/or PDR) in our
Chinese patients with T2DM and these genetic data may
contribute to risk profiling in future diabetes management. Our
findings indicated that the INSR gene is likely to be a
susceptibility candidate for severe DR and supported the
involvement of insulin resistance in the pathogenesis of DR.
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